Literature DB >> 15744170

Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients.

Bridget Hathaway1, Douglas P Landsittel, William Gooding, Theresa L Whiteside, Jennifer R Grandis, Jill M Siegfried, William L Bigbee, Robert L Ferris.   

Abstract

OBJECTIVE: Our objective was to characterize cytokine profiles in the systemic circulation of patients with active squamous cell carcinoma of the head and neck (SCCHN) compared with long-term tobacco smokers as controls. Furthermore, we hypothesized that persistent immune dysregulation in patients cured of their disease may be reflected in altered cytokine profiles in the systemic circulation. STUDY
DESIGN: Retrospective, case-control study.
METHODS: Using three well-defined clinical cohorts of SCCHN patients and smoker controls, we analyzed 100 microL of serum for a panel of 10 cytokines to determine whether serum cytokine profiles could distinguish clinically defined groups of SCCHN patients. Statistical analysis of multiplexed cytokine profiles was applied to classify three clinically defined groups: active SCCHN patients, treated SCCHN patients with no evidence of disease for over 3 years, and matched disease-free controls. Discrimination of outcome status was accomplished using classification trees, and 10-fold cross-validation was implemented to assess classification accuracy using independent data.
RESULTS: We show that multiplexed cytokine and chemokine profiling may be performed to reflect the immune status of SCCHN patients. Selected cytokine profiles indicate that immunologic responses to carcinogenesis may not normalize even in the absence of tumor for over 3 years.
CONCLUSION: Multiplexed serum cytokine profiles may be applicable to early detection, for screening those at high risk for SCCHN, and as clinically predictive biomarkers of disease status in successfully treated patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15744170     DOI: 10.1097/01.mlg.0000157850.16649.b8

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  18 in total

1.  Melatonin represses oral squamous cell carcinoma metastasis by inhibiting tumor-associated neutrophils.

Authors:  Haibin Lu; Baolei Wu; Ge Ma; Deyu Zheng; Ruijuan Song; Erjiang Huang; Ming Mao; Bin Lu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.

Authors:  Athanassios Argiris; Steve C Lee; Trevor Feinstein; Sufi Thomas; Barton F Branstetter; Raja Seethala; Lin Wang; William Gooding; Jennifer R Grandis; Robert L Ferris
Journal:  Oral Oncol       Date:  2011-09-01       Impact factor: 5.337

3.  Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

Authors:  Howard S Moskowitz; William E Gooding; Sufi M Thomas; Maria L Freilino; Neil Gross; Athanassios Argiris; Jennifer R Grandis; Robert L Ferris
Journal:  Oral Oncol       Date:  2012-06-23       Impact factor: 5.337

4.  Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma.

Authors:  Elizabeth J Franzmann; Erika P Reategui; Lutecia H Mateus Pereira; Felipe Pedroso; Debbie Joseph; Glenn O Allen; Kara Hamilton; Isildinha Reis; Robert Duncan; W Jarrard Goodwin; Jennifer J Hu; Vinata B Lokeshwar
Journal:  Head Neck       Date:  2011-07-11       Impact factor: 3.147

5.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.

Authors:  Faina Linkov; Robert L Ferris; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; William Gooding; Brian Nolan; Matthew Winans; Eric R Siegel; Anna Lokshin; Brendan C Stack
Journal:  Proteomics Clin Appl       Date:  2008-10-10       Impact factor: 3.494

6.  Methodology and applications of disease biomarker identification in human serum.

Authors:  Ziad J Sahab; Suzan M Semaan; Qing-Xiang Amy Sang
Journal:  Biomark Insights       Date:  2007-02-14

7.  Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis.

Authors:  Yoon Chan Rah; Jae-Cheul Ahn; Eun-Hui Jeon; Hyojin Kim; Jin Ho Paik; Woo-Jin Jeong; Soon-Young Kwon; Soon-Hyun Ahn
Journal:  Int J Clin Oncol       Date:  2018-05-14       Impact factor: 3.402

Review 8.  Update on molecular diagnostic tests in head and neck cancer.

Authors:  Kevin T Palka; Robbert J Slebos; Christine H Chung
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

9.  Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.

Authors:  Andrés López-Albaitero; Steve C Lee; Sarah Morgan; Jennifer R Grandis; William E Gooding; Soldano Ferrone; Robert L Ferris
Journal:  Cancer Immunol Immunother       Date:  2009-03-25       Impact factor: 6.968

10.  Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma.

Authors:  Dae-Young Hong; Byung-Joo Lee; Jin-Choon Lee; Jin-Sik Choi; Soo-Geun Wang; Jung-Hoon Ro
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-12-31       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.